Epitomee Medical Ltd (EPIT.TA)
ILA 823.2
(2.29%)
ILA 823.2
(2.29%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -7.92 Million | -9.42 Million | -5.75 Million | 6.74 Million | -2.78 Million |
| Net Income | -5.68 Million | -15.39 Million | -11.51 Million | -3.16 Million | -3.48 Million |
| Depreciation & Amortization | 639 Thousand | 356 Thousand | 235 Thousand | 231 Thousand | 194 Thousand |
| Deferred income taxes | 7.23 Million | - | - | 10 Thousand | - |
| Stock-based compensation | 994 Thousand | 1.53 Million | 1.5 Million | 287 Thousand | 383 Thousand |
| Change in working capital | -10.11 Million | -301 Thousand | 1.31 Million | 10.03 Million | 85 Thousand |
| Other non-cash items | -996 Thousand | 4.37 Million | 2.7 Million | -644 Thousand | 39 Thousand |
| Investing Cash Flow | -12.22 Million | -13.12 Million | 15.13 Million | -15.63 Million | -158 Thousand |
| Investments in PPE | -4.07 Million | -3.69 Million | -402 Thousand | -104 Thousand | -121 Thousand |
| Acquisitions | 807 Thousand | - | 51 Thousand | - | - |
| Investment purchases | -27.45 Million | -9.58 Million | -51 Thousand | -15.53 Million | -5000.00 |
| Sales/Maturities of investments | 18.44 Million | - | 15.58 Million | - | - |
| Other Investing Activities | 57 Thousand | 166 Thousand | -51 Thousand | - | -32 Thousand |
| Financing Cash Flow | -454 Thousand | -328 Thousand | 50.11 Million | 6.78 Million | 7.7 Million |
| Debt repayment | - | - | - | -7 Million | - |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 43 Thousand | - | 12 Thousand | - | - |
| Other Financing Activities | -497 Thousand | - | 50.1 Million | - | - |
| Accounts receivables | 54 Thousand | - | - | - | - |
| Accounts payables | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other working capital | -10.16 Million | - | - | - | - |
| Cash at beginning of period | 35.95 Million | 64.31 Million | 4.82 Million | 6.96 Million | 1.79 Million |
| Cash at end of period | 15.63 Million | 35.95 Million | 64.31 Million | 4.82 Million | 6.96 Million |
| Capital Expenditure | -4.07 Million | -3.69 Million | -402 Thousand | -104 Thousand | -121 Thousand |
| Effect of forex changes on cash | 276 Thousand | -5.48 Million | -93 Thousand | -37 Thousand | 411 Thousand |
| Net cash flow / Change in cash | -20.32 Million | -28.35 Million | 59.48 Million | -2.14 Million | 5.17 Million |
| Free Cash Flow | -11.99 Million | -13.11 Million | -6.16 Million | 6.64 Million | -2.9 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -1.01 Billion | -989.81 Million | -2.53 Million | -5.68 Million | -127.59 Million | -18.01 Million |
| Depreciation & Amortization | 37.37 Million | 36.52 Million | 1.16 Million | 639 Thousand | 58.55 Million | 1.19 Million |
| Deferred income taxes | - | - | - | 7.23 Million | - | - |
| Stock-based compensation | 67.01 Million | 65.48 Million | 86.56 Million | 994 Thousand | 91.35 Million | 95.43 Million |
| Change in working capital | 14.91 Million | 14.57 Million | -36.84 Million | -10.11 Million | 7.43 Million | -1.4 Million |
| Other non-cash items | 74.37 Million | 72.67 Million | 27.8 Million | -996 Thousand | -652.27 Million | 5.32 Million |
| Investing Cash Flow | 351.49 Million | 343.46 Million | 10.29 Million | -12.22 Million | 749.93 Million | -59.58 Million |
| Investments in PPE | -142.52 Million | -139.26 Million | -10.02 Million | -4.07 Million | -491.3 Million | -5.38 Million |
| Acquisitions | - | - | - | 807 Thousand | - | - |
| Investment purchases | -62 Million | - | -49.6 Million | -27.45 Million | - | -54.23 Million |
| Sales/Maturities of investments | 67.09 Million | - | 69.92 Million | 18.44 Million | - | 32.33 Thousand |
| Other Investing Activities | 494.02 Million | 482.73 Million | 1.17 Billion | 57 Thousand | 1.24 Billion | -2.71 Billion |
| Financing Cash Flow | -43.98 Million | -42.97 Million | -714.69 Thousand | -454 Thousand | -33.37 Million | -1 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | 162.63 Thousand | 43 Thousand | - | - |
| Other Financing Activities | -43.98 Million | -42.97 Million | -31.62 Million | - | -33.37 Million | -51.7 Million |
| Accounts receivables | 14.91 Million | 14.57 Million | 114.41 Thousand | - | 5.53 Million | 89.82 Thousand |
| Accounts payables | 218.04 Thousand | - | 907.17 Thousand | - | - | -10.77 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | -809.35 Thousand | - | -37.86 Million | - | 1.9 Million | -1.48 Million |
| Cash at beginning of period | 56.32 Million | - | 55.86 Million | 35.95 Million | - | 127.09 Million |
| Cash at end of period | 47.97 Million | -576.62 Million | 56.32 Million | 15.63 Million | 122.63 Million | 55.86 Million |
| Capital Expenditure | -142.52 Million | -139.26 Million | -10.02 Million | -4.07 Million | -491.3 Million | -5.38 Million |
| Effect of forex changes on cash | -78.34 Million | -76.55 Million | 27.1 Million | 276 Thousand | 28.6 Million | 23.35 Million |
| Net cash flow / Change in cash | -8.34 Million | -576.62 Million | 464.34 Thousand | -20.32 Million | 122.63 Million | -71.23 Million |
| Free Cash Flow | -961.8 Million | -939.82 Million | -21.73 Million | -11.99 Million | -1.11 Billion | -20.58 Million |
SCRSF
300243
GEECF
3678
4290
DMED